Related Experiment Videos
Cellular effects induced by the antitumor agent azinomycin B
Gilbert T Kelly1, Chaomin Liu, Roger Smith
1Department of Chemistry, Texas A&M University, College Station, Texas 77843, USA.
Abstract:
Studies on the mechanism of action of the antitumor agent azinomycin B in vitro suggest that the drug elicits its lethal effects by the formation of interstrand crosslinks within the major groove of DNA. Here, we demonstrate the biological effects of the drug in vivo. Fluorescence imaging revealed localization of azinomycin B in the nuclear region of yeast. Moreover, experiments with oligonucleotide microarrays examined the effects of the drug across the yeast transcriptome. The results demonstrated a robust DNA damage response that supports the proposed role of the drug as a covalent DNA modifying agent. RT-PCR analysis validated the gene changes, and flow cytometry of azinomycin-treated yeast cells demonstrated a phenotypic S phase shift consistent with transcriptional effects.
Insights
Azinomycin B causes DNA damage in vivo, leading to a robust DNA damage response and cell cycle changes in yeast. This study confirms its role as a covalent DNA modifying agent.
Area of Science:
- Molecular Biology
- Genetics
- Biochemistry
Background:
- Antitumor agent azinomycin B is proposed to work by forming DNA interstrand crosslinks.
- Previous studies focused on in vitro mechanisms of action.
Purpose of the Study:
- To investigate the in vivo biological effects of azinomycin B.
- To confirm its DNA-damaging mechanism in a living organism.
Main Methods:
- Fluorescence imaging to track azinomycin B localization in yeast.
- Oligonucleotide microarrays to analyze transcriptome-wide effects.
- Reverse transcription-polymerase chain reaction (RT-PCR) for gene expression validation.
- Flow cytometry to assess cell cycle progression.
Main Results:
- Azinomycin B localized to the nuclear region of yeast cells.
- Significant DNA damage response observed across the yeast transcriptome.
- RT-PCR confirmed drug-induced gene expression changes.
- Flow cytometry revealed an S phase shift, indicating transcriptional effects.
Conclusions:
- Azinomycin B elicits biological effects in vivo, consistent with its proposed mechanism.
- The drug acts as a covalent DNA modifying agent, inducing a DNA damage response.
- Transcriptional effects and cell cycle alterations are key consequences of azinomycin B treatment in vivo.
Related Concept Videos
The Intrinsic Apoptotic Pathway
Inhibitors of Bacterial Protein Synthesis
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Cellular Injury V: Apoptosis and Autophagy
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...